The science behind OncoVeryx.
OncoVeryx applies metabolomics and proprietary algorithmic analysis to identify serum metabolite patterns associated with cancer biology.
How the science works, in plain language.
What is metabolomics?
Metabolomics is the study of small molecules called metabolites. These molecules are involved in metabolism and can reflect biological processes occurring in the body.
Why serum metabolites?
Serum carries metabolites that reflect what is happening in the body. OncoVeryx reads the patterns in these metabolites that are linked to cancer.
LC-HRMS
Liquid chromatography coupled to high-resolution mass spectrometry is used to profile the metabolites present in the serum sample.
Proprietary algorithmic interpretation
Proprietary deep-learning algorithms analyse the metabolite patterns and identify the signatures associated with cancer.
Tissue-of-origin support
When a cancer-associated signature is detected, further analysis pinpoints the most likely tissue-of-origin possibilities to guide follow-up.
What the developer’s clinical validation reports.
The following figures are drawn from the PredOmix OncoVeryx clinician reference guide and are shown here for information.
Subjects in the reported prospective, multicentre, observational validation trial
Reported combined cancer detection sensitivity
Reported specificity in healthy controls
Reported tissue-of-origin accuracy
Important: These performance figures are as reported by the developer (PredOmix) in the OncoVeryx clinician reference guide. They describe the developer’s validation studies and do not guarantee individual results. No screening test is perfect. False positive and false negative results can occur. All performance claims must be reviewed against approved source documents and receive the necessary regulatory and legal sign-off before publication for South African marketing.
Broad cancer coverage. A different kind of science.
Most blood tests hunt for fragments of tumour DNA. OncoVeryx reads your body's chemistry instead, which reveals signals earlier.
individual cancers detected
cancer types and classes
simple blood sample
The cancers OncoVeryx screens for
One test screens for signals across 30 cancer types and classes, spanning 55 individual cancers, including several that have no routine screening test today.
Based on the 30 cancer types and classes in the developer’s clinical validation study. This does not mean the test detects all cancers, and a negative result does not rule out cancer.
Our approach
Metabolomics
OncoVeryx measures the small molecules your body produces, called metabolites. Cancer shifts these patterns early, even before a tumour grows large enough to shed DNA into the blood.
The usual approach
Genomics (cell-free DNA)
Most multi-cancer blood tests rely on fragments of tumour DNA. Early tumours often shed very little DNA, so these tests can miss cancers at the earliest stages.
Detects cancer across all stages, I through IV
OncoVeryx holds a high sensitivity even at the earliest stages and in people with no symptoms, where many conventional and DNA-based tests struggle. It is not evaluated for pre-cancerous (Stage 0) lesions.
Reported cancer-detection sensitivity
Sensitivity is how often a test correctly flags people who do have cancer. Higher is better.
Reported in the manufacturer's clinical validation study.
Roughly half of cancers across all stages, from separately published studies.
How to read this: these two figures come from separate studies, not a direct head-to-head trial. Different studies use different patients and methods, so the exact numbers are not perfectly comparable. The OncoVeryx figure is reported in the manufacturer’s clinical validation study. All performance and comparison claims are pending South African legal and regulatory sign-off. Screening for 55 cancers does not mean the test detects all cancers. OncoVeryx is a screening test that does not diagnose cancer: a positive result requires clinical evaluation, and a negative result does not rule out cancer.
Documents and publications.
Prepared for future downloads. Materials are shared with healthcare providers and partners on request.
Clinician Reference Guide
OncoVeryx clinical overview for healthcare providers.
Patient Brochure
Plain-language introduction for patients.
Sample Collection SOP
Blood draw, serum handling and storage protocol.
Research Publications
Peer-reviewed metabolomics and validation literature.
Regulatory Documents
Product and compliance documentation.
Screening is not diagnosis
OncoVeryx does not confirm cancer and does not rule out all cancers. False positive and false negative results can occur. Continue with routine cancer screening recommended by your healthcare provider.
Want the clinical detail?
Healthcare providers can request the OncoVeryx clinician reference guide and onboarding material.